Five Stocks To Buy According To Top Biotech-Focused Funds
Biotechnology is a very interesting industry to invest in, but also very complex.
Posts Tagged ‘Deerfield Management’
5 Stocks That Healthcare Fund Deerfield Management Was Buying in Q2
Founded by James E. Flynn in 2000, Deerfield Management has grown to become one of the premier healthcare-focused investment management companies today.
13D Filing: James Flynn’s Deerfield Management Takes 9.99% Stake in Newly-Public AveXis, Inc. (AVXS)
AveXis Inc (NASDAQ:AVXS) is the subject of a new 13D filing issued by James Flynn's Deerfield Management, which reveals a 2.24 million-share position in the stock, which you can...
Billionaire Singer Lifts Stake in Cabelas Inc. (CAB), Deerfield Bets on Beloranib, Plus Two Other Moves
Numerous closely-watched hedge fund vehicles are currently disclosing their equity positions as of the end of 2015, so individual investors can monitor what moves hedge fund managers...
Billionaires James Flynn, David Abrams, Among the Elite Investors Buying These 4 Stocks Last Week
Individual investors might find hedge fund investing quite expensive, considering the 2-and-2o fee structure most hedge funds employ.
A Look At Smart Money Three Latest Moves
In new filings with the U.S. Securities and Exchange Commission, Kelly Cardwell’s Central Square Management, James E.
Smart Money Is Seeing Upside For These Three Companies
Three companies have recently been the subject of bullish moves by hedge funds. Let us take a look at what makes these companies seem undervalued to hedgies.
Tiger Global Cuts Stake in Autohome, While Deerfield Buys More Shares of This Pharmaceutical Company
Federal funds future contracts suggest a 79% probability that the Federal Reserve will raise interest rates at the December policy meeting, an event which is expected to halt ...
Elite Hedge Funds Make Big Moves In These 3 Healthcare Stocks
A Schedule 13G is a public filing that must be submitted with the SEC by every hedge fund manager or other investor who acquires ownership of more than 5% in a publicly-traded...
Elite Hedge Funds Believe These Two Stocks Are Golden Opportunities
There are not many signals at the moment that suggest a continuation of the so-called “correction”, except for the potential letdown of the current earnings report season.
Three Healthcare Stocks Hedge Funds Are Snapping Up
Is it a good time to buy Alimera Sciences Inc (NASDAQ:ALIM)? James E.
Sequenom, Aclaris, and Xenoport Making Waves Among Elite Healthcare Investors
Three prominent healthcare-focused funds that we track at Insider Monkey submitted filings with the SEC today, disclosing new or bulked up positions in three different healthcare...
Hedge Funds’ Make Moves On Newly-Public Biotech And “Undervalued” Broker
The U.S equities markets have seriously pulled back lately, so hedge funds and other investors are stumbling upon a greater number of quality investing opportunities.
Two Stocks That Have Deerfield Management And Anchor Bolt Capital Excited
In a recent filing with the Securities and Exchange Commission (SEC), James E.
Deerfield Management Discloses 3.66% Stake In Newly Public Company Global Blood Therapeutics Inc. (GBT)
James E. Flynn’s Deerfield Management has filed a Schedule 13G disclosing a 3.66% ownership stake in the newly public company Global Blood Therapeutics Inc.
Deerfield Management Buys More And More Imprivata Inc. (IMPR) Shares
James E. Flynn’s Deerfield Management has filed a 13G with the U.S. Securities and Exchange Commission regarding its ownership of shares of Imprivata Inc. (NYSE:IMPR).
James Flynn’s Deerfield Management Ups Its Stake In Neos Therapeutics Inc. (NEOS)
James E. Flynn’s Deerfield Management disclosed that it has upped its position in Neos Therapeutics Inc.
Deerfield Management Discloses Stake In Recently Public Neos Therapeutics Inc (NEOS)
Constantly on the hunt for biotechnology stocks, James E. Flynn has identified another potential winner.
Deerfield Management Ups Passive Stake In Streamline Health Solutions Inc. (STRM) To 12.18%
Deerfield Management, led by James E. Flynn, has increased its stake in Streamline Health Solutions Inc. (NASDAQ:STRM). In a newly-amended 13G filing with the U.S.
Does James Flynn Think the Entry Point For Healthways, Inc. (HWAY) Has Arrived, And Should You Enter?
According to a recent filing with the Securities and Exchange Commission, James E. Flynn's Deerfield Management has acquired about 2.47 million shares of Healthways, Inc.
Ken Griffin And James Flynn Are Not Wasting Any Time Getting In On These New IPOs
Ken Griffin's (pictured) Citadel Investment Group has acquired about 1.09 million shares of 8Point3 Energy Partners LP (NASDAQ:CAFD).
Deerfield Management Bets Big On Company It Polished Ahead Of IPO, Nivalis Therapeutics Inc (NVLS)
Following the initial public offering of Nivalis Therapeutics Inc (NASDAQ:NVLS) today, James E.
Deerfield Management Trims Holding In Antares Pharma Inc (ATRS) Just Before Disastrous Setback
According to a recent filing with the Securities and Exchange Commission, James E.
Carbylan Therapeutics Inc (CBYL): Broadfin’s Latest Move and Market Smashing Q1 Returns Inside
To say Kevin Kotler’s Broadfin Capital had exceptional Q1 returns from its 11 long positions in companies valued at $1 billion or more would be a gross understatement.
Steadymed Ltd (STDY), Achillion Pharmaceuticals, Inc. (ACHN), & Nevro Corp (NVRO): James Flynn’s Latest Healthcare Picks
James E. Flynn of Deerfield Management, recently disclosed a stake of 1.27 million shares in Steadymed Ltd (NASDAQ:STDY).
Biotech Hedge Fund Deerfield Management’s Top Stock Picks
James E. Flynn's Deerfield Management is one of the funds that is focused on the healthcare sector, investing around 70% of its portfolio in healthcare stocks.
Tonix Pharmaceuticals Holding Corp., Manning & Napier Inc: Deerfield, Ariel Open Bullish New Positions
James E. Flynn’s Deerfield Management entered a new position in Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) this week. According to the 13G Form filed with the U.S.
Funds Reveal New Positions in Peabody Energy Corporation (BTU), BIND Therapeutics Inc (BIND)
Two of our tracked funds have recently revealed in filings with the SEC that they’ve taken large new passive positions in a couple of stocks.
Auspex Pharmaceuticals Inc (ASPX): Deerfield Management Increase its Stake Following the Latest Public Offering of Stock
James E. Flynn’s Deerfield Management recently increased its stake in Auspex Pharmaceuticals Inc (NASDAQ:ASPX) by 1.5 million shares at $56.5 per share.
Alcobra Ltd (ADHD): Broadfin Capital and Deerfield Initiate Passive Stakes Following Public Offering
Kevin Kotler's Broadfin Capital and James Flynn's Deerfield Management have both initiated passive stakes in Alcobra Ltd (NASDAQ:ADHD).
Vanda Pharmaceuticals Inc (VNDA): Deerfield Management Increases Exposure Following Positive Announcement
James Flynn’s Deerfield Management disclosed an increase in its stake in Vanda Pharmaceuticals Inc (NASDAQ:VNDA) on Friday.
Synergy Pharmaceuticals Inc (SGYP), Proteon Therapeutics Inc (PRTO): James E. Flynn and Peter Kolchinsky Think These Stocks Look Healthy
Synergy Pharmaceuticals Inc (NASDAQ:SGYP) and Proteon Therapeutics Inc (NASDAQ:PRTO) are in the spotlight as James E.
BioScrip Inc (BIOS), Proteon Therapeutics Inc (PRTO): GAMCO Investors and Deerfield Management Are Bullish on These Companies
Mario Gabelli’s GAMCO Investors and James E.
Alimera Sciences Inc (ALIM) & Bio Blast Pharma Ltd (ORPN): 2 Pharmaceutical Stocks Hedge Funds are Increasing Their Stakes In
Pharmaceuticals and life sciences as a sector is where most of the money from hedge funds seems to be flowing in.
Entegris Inc (ENTG), Dicerna Pharmaceuticals Inc (DRNA): GMT Capital and Deerfield Management Report Their Latest Moves
In two new filings, Thomas E. Claugus' GMT Capital disclosed further raising its exposure to Entegris Inc (NASDAQ:ENTG).
Keryx Biopharmaceuticals (KERX): Baupost Group Boosts Its Stake
Seth Klarman is bullish on Keryx Biopharmaceuticals (NASDAQ:KERX) and his fund, Baupost Group, has recently surged its position in the company.
PowerSecure International Inc. (POWR), Anthera Pharmaceuticals Inc (ANTH): Broadfin Capital and Becker Drapkin Management’s Recent Bullish Moves
Last Friday, Kevin Kotler’s Broadfin Capital disclosed a marked increase (of almost 70%) in its exposure to Anthera Pharmaceuticals Inc (NASDAQ:ANTH).
Visium Asset Management and Deerfield Management Are Bullish About These Stocks
Two Schedule 13G forms filed with the SEC yesterday called my attention.
Loxo Oncology Inc (LOXO): Deerfield Management Discloses 13.65% Activist Stake
Samuel Isaly's Orbimed Advisors has disclosed holding a stake in Loxo Oncology Inc (NASDAQ:LOXO).
AMAG Pharmaceuticals Inc. (AMAG): Deerfield Management Boosts Stake to Nearly 6%
Deerfield Management, managed by James E. Flynn, has disclosed upping its stake in AMAG Pharmaceuticals Inc. (NASDAQ:AMAG). A new filing with the U.S.
Deepak Gulati’s Argentiere Capital’s Top Stock Picks
Zug, Switzerland-based Argentiere Capital is an alternative investment management firm, which was founded by Deepak Gulati. Mr.
Deerfield Management Ups Stake in Aerie Pharmaceuticals Inc (AERI)
In a new filing with the Securities and Exchange Commission, James E. Flynn of Deerfield Management, has revealed a 6.05% stake in Aerie Pharmaceuticals Inc (NASDAQ:AERI).
James E. Flynn’s Deerfield Management Reveals Passive Stake in Amphastar Pharmaceuticals Inc. (AMPH)
James E. Flynn, the manager of Deerfield Management, has disclosed a new passive stake in Amphastar Pharmaceuticals Inc. (NASDAQ:AMPH). Mr.
Felix Baker Raises Stake in Synageva BioPharma Corp (GEVA) Through Convention of Options
As a new form 4 filing with the Securities and Exchange Commission showed, Julian and Felix Bakers' Baker Bros Advisors, a fund focused on the biotechnology and healthcare companies...
Deerfield Management Discloses New Position in ANI Pharmaceuticals Inc (ANIP)
James E. Flynn's Deerfield Management reported a new stake in ANI Pharmaceuticals Inc (NASDAQ:ANIP).
Deerfield Ups Stake In Trivascular Technologies Inc (TRIV)
Deerfield Management, managed by James E. Flynn, has revealed raising its position in Trivascular Technologies Inc (NASDAQ:TRIV).
Deerfield Management Reveals Position in Newly Public Company Trivascular Technologies Inc (TRIV)
As a new filing with the Securities and Exchange Commission showed, Deerfield Management, a healthcare focused investment firm, managed by James E.
Hedge Fund Resource Center
